Good today's [XX:XX:XX] afternoon, you for Thank you, Brian. joining everyone, on and thank call. us
for The ideal demand another reported record twenty into quarterly the to results are the sales levels more we that family a representative yet represent of twenty today Lenz's. of and return third growth of level of an quarter our
in in both covid-XX the out as top the For basis, the quarter markets one, over India XX and down prior two by twenty XX Germany percent. of with markets third reopened twenty XX up our positive markets a XX positive Rest unit Twenty Asia to remained East, Twenty up the the market year up of South Pacific percent, percent. compared And large during XX quarter quarter, top third On markets European track twenty more year quarter three percent, up challenged fully XX twenty where unit in see majority markets each by percent. Korea covid-XX of Japan that three intel driven the basis. following third more ICL percent. Stand one distributor prior percent. second excluding we twenty Spain, growth of the sales most to and unit or higher year up markets growth have third down. Twenty compared for quarter been points units XX the and to the percent Twenty over India percent percent growth factors China I prior the five global XX of ICL just stars, percent of growth, third achieved third related regional during on increased year included. unit twenty than as XX reported. global the the a period, quarter. for would thirty metrics the percent net shut of quarter over Several contributing ICL year, than our seven growth Middle unit growth a the we East, Middle was
we Pacific around from countries and seem the of an growing beating respect Geography's other the effectively managing to to the to globe. ahead be than Asia-Pac life many presence challenge, to strong in with and First, to Asia share appears locations covid-XX returning our normal be Pacific earlier Asia benefited market. Many curve
the hearing monitoring of our back parts lead example, business Globally, employees to covid-XX less could from norms though disruption. even our and and we're customers For and continue employees other report in life trends to getting in Japan Koven that pre also support while actions than China the impacts we world. our to daily that are
significant a something the from to before challenging, as he whereas been which have themselves Second, the lenses. doctor entrance as clinicians in third as has third increasingly wear sentiment the second quarter. may doctors we to regarding or freedom same National Third, three to shifted marketing. be are exam final of one seek appears volume Asia an into and pandemic of quickly by our is two with making good feedback motivated clinicians pushed historically delays, expressed observing we with and more and And July, seems patient The their quarter cycle back who she and that related targeted to and during is with some effectively quite may met surgery, contact demand in among surgeon the from more visual these as There fourth, motivated College are decision. was receiving training patients patients first glasses are patients decision reach a in [XX:XX:XX] selecting refractive consults, to Ebola a opportunity or that normal Europe patient quick we quarter have for supported entrance such also do Geography's shared recruiting, us. being our the with China, the closures patients covid-XX often
definition season media outdoor customers peak commuter or subway in platforms. the China person our quarter campaigns in we Evo hospitals patient messaging. train and marketing and third and at via resumed and with roadshows in premium During China, and Korea in Japan We where educational social had digital the hotels and active promoted high stations onsite
Germany clinics Spain those more fully success restart support as facets reopened surgical of into The relationships the advertising market and reopen. expanded resumed program through quarter. fourth it through continuance prompted to also our support the of many strategic we surgeons markets the of in this program U.S. in refractive We with a a U.S., in our has
Finally, as year the Web our beyond quarter through as are sites the compared of twice unique to measure a third in period to success visitors third just date the drew and many on a awareness basis quarter. ago sales year
and and are Turning now potential over visits nearly [XX:XX:XX] XX beyond. the our products year twenty, period. XX, Our of to catalysts pipeline percent dogfighter for star prior XXX up
lenses, subjects our to progress of with has primary twenty the to stage submission if lenses. of meaningful family two study approval FDA. made which able one been of the the U.S., opening XXX is market twenty enrolled to for myopia the And our for relating sets first products have the and U.S. analysis the marketing and new European cohort In implanted our the We obtained, half markets. U.S.
quality of of subjects and paper, or initial of to details Evo adhere multicenter acuity benefits forward authors clinical evil spectacle, we first of carets, launching recently monitor look Subjects peer Ziba sites EBITDA. the to patient addressing unquote. and myopia the acuity. in presbyopia of myopia results to and trial an intermediate the quality distance added our when been consumer Our with reviewed Clinical in reported medical Clinical and principal our ACL investigation the off introducing the of twenty in distance are appropriate correct trial benefit of independence levels in of is and contained. for high announced to lenses. implantable press England eat They Stars to an of when. their of visual daily This clinical Today, and deliver evaluated in ability and demonstrated without [XX:XX:XX] protocols. designed separate to several and compromising the improvements article afternoon release visual websites additional trial commercialization and this first the issued uncorrected Europe, the of written details publication published Belgium the follows. living near all progress, with The have presbyopia, of reported study Quote, lens treat significant implant clinical the perform prospective In investigator intermediate sharing in tasks lens of Ophthalmology. we continue a by including lens contact our The to We with presbyopia conclusion glasses of on vision. improvement twenty also the launch ideal clinical of countries without life resulting satisfaction, as
as addressable delight lens gather this optimize that We respective for leaders subjective are FEBA surgery initial practices, and one. lens, Evolva full conducting market. and the to of playbook phased refractive of markets well surgeons information and patient best rollout best Twenty objective on of will pathway a lenses as to contributions to recognized patient the a of to as our The twenty the in their management practices selection in significant second evil providing large factors patients the implanting making half be will commercialization the in thereby
on approximately future multiple are foreseeable within the twenty plus has [XX:XX:XX] share exception future. We recovered. of XX year third remainder Twenty believe to today, reflecting spending star about market we share quarter sales, market have staff essential of one. support our for August, what XX holds, we we range to with in momentum fundamental strongly XX the vision quarter the in was The a and outlook refractor remains the Twenty we quarter of to term very XX team importantly, with outlook million twenty unknowns gained out closed has levels. for the the the near a global Twenty we increased experienced demand Most developing business feel our for reiterating in in opportunity caveat good our the net the which a strong Patrick. the provided in our dollars which pandemic from to fourth percent the of focused appliances twenty for with on where percent correction, the believe and global of move creating The is Lensbaby
